Good MorningThe equity market continues to drift sideways near the recently set all-time high while traders wait on the next cues for the market. The Dow Jones Industrial Average closed with a small loss while the NASDAQ Composite and S&P 500 both eeked out small gains. On the one hand, traders are hopeful another round of stimulus will juice an already strong economic rebound while on the other the risks of COVID continue to weigh on the economy.
The newest round of stimulus is expected to be signed into law by mid-March and will include another check for most Americans. One of the final sticking points to be decided is who, exactly will get another check. Also to be included in the bill is an increase to the minimum wage and an extension of unemployment benefits.
Featured: The 7 Stocks Quietly Gaining Attention Right Now (Ad) 
|
Energy | |
With so many people focused on renewable energy companies these days, oil & gas stocks have largely become an afterthought for investors. While it’s safe to say that the rise of clean energy is a long-term trend worth buying into, that doesn’t mean that oil & gas companies can&... Read the Full Story |
|
From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
|
Markets | | Steel producer United States Steel Corporation (NYSE: X) stock has seen a strong surge in 2021 followed by a sharp decline but still performing well against the benchmark S&P 500 index (NYSEARCA: SPY). The demand for steel is bolstered by the recovering automotive market, housing, construction, ... Read the Full Story |
|
Consumer Discretionary | | Tier 1 automotive parts supplier American Axle and Manufacturing Holdings (NYSE: AXL) stock is slowly recovering back towards pre-COVID 19 levels. Shares underperformed the benchmark S&P 500 index (NYSEARCA: SPY)mostly from resonating effects of the pandemic. As COVID-19 caseloads start to retra... Read the Full Story |
|
From Our Partners | | Matt Monaco started with a $2,000 trading account and no clear strategy. After two years of trial and error, he crossed $1 million in 2020.
Today his account sits at $3 million, generating roughly $100,000 a month using a repeatable system he calls The Income Blueprint.
He's revealing the exact five-step scan and three trading lanes behind it in a free live training. | | Reserve your seat and claim The Income Blueprint free |
|
Healthcare | |
Many investors consider the health care sector to be a great place to be in for the long-term. The aging of the world's population, pharmaceutical breakthroughs, and medical research discoveries are all expected to be growth drivers for some time.
But putting 2021 under the microscope, there are ... Read the Full Story |
|
Markets | | Cannabis Stocks: Follow The Money But Don’t Chase Prices
With the cannabis market back in the spotlight we thought it might be a good idea to highlight some of the lesser-known and perhaps underloved names in the sector. Who knows, maybe we’ll turn up a great investment but in the meant... Read the Full Story |
|
From Our Partners | | Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film.
Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | | Watch the full investigation and decide for yourself |
|
Communication Services | | Shares of Disney (NYSE: DIS) are on track to cross the $200 mark for the first time in the next few sessions after reporting fiscal Q1 earnings last night that took Wall Street by surprise. GAAP EPS was firmly in the black at $0.02 after an impressive beat by $0.73 that helped stave off a loss marki... Read the Full Story |
|
Consumer Discretionary | | Toyota Is Gearing Up For A Big Move
With OEM auto manufacturers and start-ups around the world ramping production of electric vehicles, it is no surprise to hear Toyota (NYSE:TM) is doing the same. Recently criticized for its focus on hybrid vehicles, the company is shifting that focus to battery-e... Read the Full Story |
|
Industrials | | Demand And Low Inventory Drive iRobot Results
iRobot’s (NASDAQ:IRBT) Q4 performance has helped gel an idea we’ve been kicking around. The idea is that demand for consumer goods has been so strong that, when coupled with widespread manufacturing shut-downs, store shelves are wiped out of... Read the Full Story |
|
Markets | | Land-based and digital gaming company Everi Holdings (NYSE: EVRI) stock is started to get “discovered” by investors looking for exposure in the recovery of casino gaming and acceleration in iGaming legalization. The momentum in digital sports betting and iGaming platforms like Penn Natio... Read the Full Story |
|
Healthcare | |
With the S&P 500 soaring to record levels over the past year, most of its constituents' dividend yields aren't what they used to be. However, there are still some juicy high yielding stocks to consider.
With a lofty dividend return often comes skepticism as to whether a company's dividend is ... Read the Full Story |
|
The Early Bird Stock Of The Day Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. | | View Today's Stock Pick |
|
